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The proton pumping H-ATPase, Pma1p, is an abun-
dant and very long-lived polytopic protein of the Sac-
charomyces cerevisiae plasma membrane. Pma1p consti-
tutes a major cargo of the secretory pathway and thus
serves as an excellent model to study plasma membrane
biogenesis. We have previously shown that newly syn-
thesized Pma1p is mistargeted to the vacuole in an elo3
mutant that affects the synthesis of the ceramide-bound
C26 very long chain fatty acid (Eisenkolb, M., Zenz-
maier, C., Leitner, E., and Schneiter, R. (2002) Mol. Biol.
Cell 13, 4414–4428) and now describe a more detailed
analysis of the role of lipids in Pma1p biogenesis. Re-
markably, a block at various steps of sterol biosynthesis,
a complete block in sterol synthesis, or the substitution
of internally synthesized ergosterol by externally sup-
plied ergosterol or even by cholesterol does not affect
Pma1p biogenesis or its association with detergent-re-
sistant membrane domains (lipid “rafts”). However, a
block in sphingolipid synthesis or any perturbation in
the synthesis of the ceramide-bound C26 very long chain
fatty acid results in mistargeting of newly synthesized
Pma1p to the vacuole. Mistargeting correlates with a
lack of newly synthesized Pma1p to acquire detergent
resistance, suggesting that sphingolipids with very long
acyl chains affect sorting of Pma1p to the cell surface.
Integral membrane proteins destined to the cell surface en-
ter the membrane in the ER1 and are then transported along
the secretory pathway to the plasma membrane. Along this
route, the quality of the transported cargo is monitored at
several steps to ensure that only functional proteins are deliv-
ered to the cell surface. Surface delivery of membrane proteins
is likely coupled to expansion of the plasma membrane itself,
implying that transport and sorting of proteins may be linked
to that of lipids. Whereas the mechanisms that survey protein
sorting and quality control are being studied intensively, the
fate of lipids along this route and their possible roles in protein
sorting and maturation are less well understood (1, 2).
The proton pumping H-ATPase, Pma1p, is an abundant
and long-lived polytopic membrane protein of the yeast plasma
membrane. Due to its abundance at the cell surface, Pma1p
constitutes a major cargo of the secretory pathway and thus
may serve as a model to study plasma membrane biogenesis (3,
4). Pma1p is biosynthetically inserted into the ER membrane,
where it homo-oligomerizes to form a 1.8-MDa complex that
resists extraction by detergents (5). This protein-lipid complex
is then packaged into a larger subclass of COPII transport
vesicles that contain Lst1p instead of Sec24p (6). From the
Golgi complex, Pma1p is transported to the cell surface by a
branch of the secretory pathway that does not intersect with
endosomes (7, 8). At the cell surface, Pma1p becomes stabilized
and occupies domains that are distinct from those occupied by
the arginine/H symporter Can1p (9).
Similar to the synthesis of integral membrane proteins, the
synthesis of sphingolipids commences in the ER, where serine
palmitoyl transferase catalyzes the condensation of serine with
palmitoyl-CoA to form a long chain base. The long chain base
then condenses with a C26 very long chain fatty acid to form
ceramide in a reaction that requires LAG1, LAC1, and LIP1
(10–12). From the ER, ceramide is transported both by vesic-
ular and non-vesicular routes to the Golgi, where it is converted
to sphingolipids (13, 14). Mature sphingolipids are then trans-
ported to the plasma membrane, where they are highly en-
riched (15–17).
The ceramide-bound C26 very long acyl chain is synthesized
by elongation of saturated long chain fatty acids by an ER-
associated acyl chain elongation complex containing Elo2p/
Fen1p, Elo3p/Sur4p, Tsc13p, Ybr159p, and soluble factors such
as palmitoyl-CoA (Acb1p) and malonyl-CoA (synthesized by
Acc1p), which provide the substrates for elongation (18–22).
The physiological significance of the very long chain fatty acid
substitution on the fungal ceramide is unknown, but it has
been speculated that the length of the transmembrane domain
of proteins along the secretory pathway may increase to match
bilayers of increasing “thickness” (14). In such a model, the
abundance of C26-containing lipids may determine the thick-
ness of membranes along the secretory pathway.
A relationship between Pma1p biogenesis and lipid synthesis
is indicated by a number of observations. Long chain base or
ceramide synthesis is required for oligomerization and raft
association of Pma1p in the ER (5, 23). Oligomerization of
Pma1p, however, is not required for ER export or surface de-
livery but might be important for stabilization of the protein
once it has reached the cell surface (5, 23). In addition, raft
association of Pma1p is important for its proper surface target-
ing and for the subsequent stabilization of the protein at the
cell surface (23–25).
We have previously observed that newly synthesized Pma1p
is mistargeted to the vacuole in a mutant that affects acyl chain
elongation and hence C26 synthesis (elo3/sur4) (26). The aim
of the present study was to characterize the role of lipids and
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particularly that of the C26 very long chain fatty acid in surface
transport of Pma1p in more detail. Pulse-chase analyses to
follow Pma1p biogenesis in various lipid biosynthetic mutants
indicate that any reduction in the efficiency of the fatty acid
elongation pathway results in destabilization of newly synthe-
sized Pma1p. These results suggest that ceramide levels and/or
their substitution with saturated very long chain fatty acids is
important for proper routing of Pma1p to the cell surface.
EXPERIMENTAL PROCEDURES
Yeast Strains and Growth Conditions—Yeast strains used in this
study are listed in Table I. Strains bearing single deletions of nones-
sential genes were obtained from EUROSCARF (see www.rz.uni-frank-
furt.de/FB/fb16/mikro/euroscarf/index.html) (27). Strains were culti-
vated at 24 °C, 30 °C, or 37 °C in YPD-rich media (1% Bacto yeast
extract, 2% Bacto peptone (USBiological, Swampscott, MA), 2% glucose)
or in minimal media. Selection for the kanMX marker was on media
containing 200 g/ml G418 (Invitrogen). Unless otherwise noted, chem-
icals were purchased from Sigma. Aureobasidin A was obtained from
Takara Bio Inc. (Shiga, Japan), myriocin and fumonisin B1 were from
Alexis Corp. (Lausen, Switzerland), and terbinafine was a kind gift
from N. Ryder (Novartis Research Institute, Vienna, Austria). Media
supplemented with sterols contained 5 mg/ml Tween 80 and 20 g/ml
ergosterol or cholesterol. hem1 mutant cells were supplemented with
10 g/ml -aminolevulinic acid (ALA).
For DNA cloning and propagation of plasmids, Escherichia coli strain
XL1-blue (Stratagene) was used. To generate double mutants with
pep4, a pep4::LEU2 disruption cassette (pTS17; Tom Stevens, Univer-
sity of Oregon, Eugene, OR) was cut with BamHI and used for trans-
formation of elongase mutants. PEP4 disruption was confirmed by PCR
and a plate assay for carboxypeptidase Y activity. To generate the
hem1mutant, the plasmid pHEM1-LEU2 containing the hem1::LEU2
disruption cassette (kindly provided by I. Hapala, Slovak Academy of
Sciences, Bratislava, Slovak Republic) was cut with BamHI/HindIII to
release the disruption cassette, and transformants were selected on
minimal media without leucine but supplemented with ALA. Correct
insertion of the disruption cassette at theHEM1 locus was confirmed by
phenotypic analysis, i.e. growth on ALA-supplemented media, but no
growth on non-supplemented media. The plasmid containing a GFP-
tagged version of Pma1p was kindly provided by A. Breton (Institut de
Biochimie et Genetique Cellulaires, Bordeaux, France) (28).
Generation of Anti-Pma1p Antisera—To generate antibodies against
Pma1p, plasma membranes were isolated from wild-type cells by frac-
tionation over a sucrose density gradient (29). Plasma membrane pro-
teins were then separated by SDS-PAGE, and the region corresponding
to Pma1p was excised and used to immunize rabbits provided and
maintained by Eurogentec (Seraing, Belgium).
Pulse-chase Analysis—For pulse-chase analysis, cells were grown to
A600  1 in minimal media lacking cysteine and methionine; unless
otherwise noted the culture was then split and pre-incubated at either
24 °C or 37 °C for 15 min. Cells were pulsed with 100 Ci/ml
EXPRE35S35S protein labeling mix (1175 Ci/mmol; PerkinElmer Life
Sciences) for 5 min. Chase was initiated by addition of chase solution
(100; 0.3% cysteine, 0.3% methionine, 300 mM ammonium sulfate). At
each time point, 5 A600 units of cells were removed, placed on ice, and
arrested with 20 mM NaN3/NaF. Cells were centrifuged; resuspended in
50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 10 g/ml leupeptin A, and 10
g/ml pepstatin; and disrupted by vortexing with glass beads. SDS was
added to 1%, and the lysate was incubated at 45 °C for 10 min. The
lysate was diluted by addition of 800 l of TNET (30 mM Tris-HCl, pH
7.5, 120 mM NaCl, 5 mM EDTA, and 1% Triton X-100) and centrifuged
at 15,000  g for 10 min. The supernatant was incubated with anti-
Pma1p antibody and protein A-Sepharose. Immunoprecipitates were
analyzed by SDS-PAGE, visualized with a phosphorimager, and quan-
tified using the Quantify One software (Bio-Rad).
Detergent resistance of newly synthesized Pma1p was examined as
previously described (25, 26). Lysates of labeled cells (3–4 A600 equiv-
alents) were extracted with 1% Triton X-100 for 30 min at 4 °C. Samples
were centrifuged at 100,000 g for 1 h. Pellets were resuspended in 1%
SDS. Detergent concentrations in aliquots of total, supernatant, and
pellet samples were adjusted for immunoprecipitation.
All pulse-chase analyses were performed at least two times with
essentially the same results. Deviations between independent experi-
ments were generally 10%.
Fluorescence Microscopy—In vivo localization of GFP-tagged Pma1p
was performed by fluorescence microscopy using a Zeiss Axioplan 2
microscope (Carl Zeiss, Oberkochen, Germany) equipped with an Axio-
Cam charge-coupled device camera and AxioVision 3.1 software.
Lipid Analysis—Sterol synthesis was monitored by labeling cells
with 10 Ci/ml L-[methyl-3H]methionine (85 Ci/mmol; American Radio-
labeled Chemicals Inc., St. Louis, MO) for 2 h at 37 °C. Cells were
resuspended in methanol, and non-saponifiable lipids were extracted
with heptane and analyzed by thin layer chromatography on Silica Gel
60 plates (Merck) using cyclohexane:diethylether:glacial acetic acid (40:
159:1, v/v/v) as solvent system. Incorporation of radiolabel into newly
synthesized sterols was quantified by one-dimensional radioscanning
with a Berthold Tracemaster 40 Automatic TLC-Linear Analyzer, and
plates were visualized using a phosphorimager (Bio-Rad).
RESULTS
Synthesis of Inositolphosphorylceramide Is Required for Sur-
face Delivery of Pma1p—The fact that long chain base synthe-
sis is required for Pma1p biogenesis, together with our previ-
ous observation that Pma1p is conditionally destabilized in an
elo3/sur4 mutant, indicates that Pma1p biogenesis is lipid-
dependent (5, 23, 24, 26). To examine this lipid requirement in
more detail, we first examined Pma1p stability in wild-type
cells treated with inhibitors of essential steps along the sphin-
golipid biosynthetic pathway (Fig. 1). Myriocin (20 g/ml) was
used to block long chain base synthesis, fumonisin B1 (72
g/ml) was used to block ceramide production, and aureobasi-
TABLE I
S. cerevisiae strains used in this study
Strain Relevant genotype Source
BY4742 MAT his31 leu20 ura30 lys20 EUROSCARF (27)
MAT his31 leu20 ura30 lys20 xyz::kanMX EUROSCARF (27); xyz indicates a deletion in
a nonessential gene used in this study
RH2607 MATa his4 leu2 ura3 bar1 lcb1–100 H. Riezman (33)
YRS1593 MATa leu2 ura3 lys2 trp1 tsc13ts T. Dunn (19)
YRS1041 MATa ade2–101 ura3–52 leu2-1 lys2–801 acc1ts Ref. 22
YRS1550 MAT his31 leu20 ura30 lys20 elo3::his5MX6
pep4::LEU2
Ref. 26
YRS1707 MAT his31 leu20 ura30 lys20 hem1::LEU2 This study
YRS1714 MAT his31 leu20 ura30 lys20 elo2::kanMX4
pep4::LEU2
This study
YRS1546 MAT? his3200 leu21 ura3–52 trp163
pep4::URA3
This study
YRS1718 MAT his31 leu20 ura30 lys20
acb1::kanMX4 pep4::LEU2
This study
YRS1716 MATa leu2 ura3 lys2 trp1 tsc13–1 pep4::LEU2 This study
YRS1917 MATa ade2–101 ura3–52 leu2-1 lys2–801 acc1ts
pep4::LEU2
This study
YRS1986 MATa his4 leu2 ura3 bar1 lcb1–100 elo3::kanMX4 This study
YRS1825 MAT his31 leu20 lys20 ura30 are1::kanMX4
are2::HIS3MX6
This study
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din A (2 g/ml) was used to inhibit the conversion of ceramide
to inositolphosphorylceramide (IPC) (30–32). Cells were pre-
incubated with each of these drugs for 15 min at 24 °C, split,
incubated at either 24 °C or 37 °C for 15 min, and pulse-labeled
with [35S]methionine and [35S]cysteine for 5 min in the pres-
ence of the drugs. The stability of newly synthesized Pma1p
was then monitored 0, 30, and 60 min after the addition of
unlabeled chase solution. This analysis revealed that Pma1p is
degraded in cells treated with each one of these inhibitors,
indicating that sphingolipid synthesis up to IPC is required for
stable production of Pma1p. The shift to 37 °C for 15 min was
included to replicate the conditions under which Pma1p is
degraded in elo3mutants, and under the experimental regime
used here, the temperature shift was required to destabilize
Pma1p (Fig. 2A) (26). The temperature dependence of drug
action was not limited by the time of drug pre-incubation be-
cause even 1 h of drug pre-treatment did not result in any
significant destabilization of newly synthesized Pma1p when
cells remained at 24 °C (data not shown).
lcb1-100 and elo3 affect detergent solubility of newly syn-
thesized Pma1p (5, 23, 26). lcb1-100 encodes a temperature-
sensitive subunit of the serine palmitoyl transferase and can be
employed to conditionally block long chain base synthesis (33).
To determine whether a block in sphingolipid biosynthesis also
affects detergent solubility of newly synthesized Pma1p, the
fate of Pma1p was examined in pep4mutant cells, which lack
a major vacuolar hydrolase and thus fail to degrade Pma1p
that has been mistargeted to the vacuole. Cells were treated
with inhibitors of sphingolipid synthesis and pulse-labeled at
either 24 °C or 37 °C, and the membrane pellets were extracted
with cold Triton X-100 to generate detergent-soluble and de-
tergent-resistant pellet fractions. Pma1p was then immunopre-
cipitated from these fractions, and the proportion of Pma1p
was compared with a non-detergent-treated control (total).
This analysis revealed that in wild-type cells, a large propor-
tion (50%) of newly synthesized Pma1p already becomes de-
tergent-resistant at 5 min after pulse-labeling, and this pool of
Pma1p further increases over time (Fig. 2B). In cells treated
with the inhibitors and pulse-labeled at 37 °C, however, the
majority of newly synthesized Pma1p was present in the de-
tergent-soluble fraction at the 5 min time point, and only a
small increase in the proportion of Pma1p that resisted deter-
gent extraction was observed over time. This loss of detergent
resistance was temperature-dependent because it was not ob-
served when cells were labeled and chased at 24 °C. Taken
together, the results of this analysis indicate that drug-induced
mistargeting of newly synthesized Pma1p is temperature-de-
pendent and correlates with the failure of Pma1p to acquire
detergent resistance. The pharmacological block in sphingo-
lipid synthesis thus results in the same conditional phenotype
as previously observed in an elo3 mutant (26).
Defects or a Block in Sterol Synthesis Does Not Affect Pma1p
Biogenesis—Sphingolipids associate with sterols to form mem-
brane domains that resist detergent extraction (34). To test
whether synthesis of the fungal sterol, ergosterol, is important
for Pma1p biogenesis and acquisition of detergent resistance,
the stability of newly synthesized Pma1p was examined in
viable mutants in the post-squalene part of the ergosterol bio-
synthetic pathway (35). Pulse-chase analysis revealed that
Pma1p was stable in all erg mutants tested (erg24, erg3,
erg4, erg5) (Fig. 3A). To determine whether a block in ergos-
terol biosynthesis as imposed by terbinafine, an inhibitor of the
fungal squalene epoxidase (36), affects Pma1p biogenesis, cells
that lack endogenous steryl esters due to mutations in the two
steryl ester synthetases, ARE1 and ARE2 (37), were treated
with terbinafine (30 g/ml) for different periods of time, and
turnover of Pma1p was examined by pulse-chase labeling and
immunoprecipitation. are1 are2 double mutant cells were
employed to prevent the rapid replenishment of a depleted
FIG. 1. Overview of the sphingolipid biosynthetic pathway of
yeast. Schematic diagram of the sphingolipid pathway with inhibitors
of essential steps, genes, and biosynthetic intermediates indicated. See
the reviews cited under “Introduction” for further details. myr, myriocin;
fumB, fumonisin B1; AbA, aureobasidin A; 3-KS, 3-ketosphingosine; DHS,
dihydrosphingosine; PHS, phytosphingosine; DHC, dihydroceramide; PHC,
phytoceramide; MIPC, mannosyl-inositolphosphorylceramide; M(IP)2C,
mannosyl-diinositolphosphorylceramide.
FIG. 2. Inhibition of sphingolipid synthesis induces condi-
tional turnover of newly synthesized Pma1p. A, wild-type cells
(BY4742) were cultivated in media lacking methionine and cysteine at
24 °C. Cells were incubated with myriocin (20 g/ml), fumonisin B (72
g/ml), or aureobasidin A (2 g/ml) for 15 min at 24 °C, split, and
incubated in the presence of drugs at either 24 °C or 37 °C prior to
pulse-chase analysis and immunoprecipitation. Quantification of
Pma1p levels is shown in the graphs. B, PEP4 mutant cells (YRS1546)
were incubated with the indicated drugs at 24 °C for 15 min, shifted to
37 °C for 15 min, and pulse-labeled. Samples were removed at the
indicated time points after chase addition and split into a total fraction
(T) and a fraction that was extracted with 1% Triton X-100 for 30 min
on ice. The detergent fraction was centrifuged at 100,000  g for 1 h to
yield a detergent-resistant pellet (P) and a soluble (S) fraction. Pma1p
was immunoprecipitated and analyzed by gel electrophoresis. Quanti-
fication of Pma1p levels in the detergent-resistant pellet as a function
of temperature and time is shown in the graphs. The data shown in A
and B represent one of two independent experiments with essentially
the same results.
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ergosterol pool by steryl ester hydrolysis (38). Remarkably,
Pma1p stability was unaffected in cells treated with terbin-
afine for up to 4 h prior to pulse-chase labeling (Fig. 3B). Under
these conditions, endogenous synthesis of ergosterol is com-
pletely blocked, as determined by labeling cells with [3H]me-
thionine and the analysis of radiolabeled ergosterol (Fig. 3C).
Pulse-chase analysis followed by detergent extraction revealed
that Pma1p acquired detergent resistance even in cells that
were blocked in ergosterol synthesis (Fig. 3C). To examine
whether Pma1p synthesized under these conditions is indeed
transported to the cell surface rather than accumulated in an
intracellular location, we examined the subcellular distribution
of a GFP-tagged version of Pma1p. erg mutants expressing
Pma1p-GFP were cultivated for 2 h at 37 °C and then analyzed
by fluorescence microscopy. Pma1p-GFP exhibited prominent
ring-like staining at the cell periphery, indicative of its plasma
membrane localization. Only faint staining of vacuolar struc-
tures was occasionally observed (Fig. 3D). are1 are2 double
mutant cells expressing Pma1p-GFP were treated with terbi-
nafine for various time periods and examined by fluorescence
microscopy. Again, only ring staining of the plasma membrane
was observed, indicating that the stable biogenesis of Pma1p
observed by pulse-chase analysis is indicative of cell surface
transport rather than due to intracellular accumulation of the
protein. Taken together, these results indicate that sphingo-
lipid synthesis up to IPC, but not the structure or even synthe-
sis of ergosterol, is important for Pma1p to acquire detergent
resistance and to be sorted to the cell surface.
ER Synthesis of Ergosterol Is Dispensable for Surface Deliv-
ery of Pma1p—Because a terbinafine-induced block inhibits de
novo synthesis of ergosterol but does not affect the pool of
pre-existing ergosterol, we examined a possible role of ergos-
terol in surface delivery of Pma1p using hem1 mutant cells.
Heme deficiency effectively mimics anaerobic conditions and
renders yeast auxotroph for sterols and unsaturated fatty acids
because their synthesis requires molecular oxygen (39, 40).
Hem1p catalyzes the first step in heme biosynthesis, the con-
version of glycine and succinyl-CoA to ALA (39). Deficiency in
HEM1 can thus be overcome by supplementing cells with ste-
rols and unsaturated fatty acids, thereby mimicking anaerobic
conditions; alternatively, the biosynthetic block can be by-
passed by providing cells with ALA, thereby allowing heme
biosynthesis. To examine Pma1p stability in cells lacking the
capacity to synthesize their own ergosterol, hem1 mutant
cells were cultivated in the presence either of ALA, ergosterol,
or cholesterol, and the stability of Pma1p was determined by
pulse-chase labeling and immunoprecipitation. This analysis
revealed that newly synthesized Pma1p remained stable in the
heme mutant cells even when cells were grown in the presence
of cholesterol over many generations (Fig. 4). Examination of
FIG. 3. Sterol requirement for Pma1p stability. A, mutations in
the ergosterol biosynthetic pathway do not affect the biogenesis of
Pma1p. Mutants at different steps of the ergosterol pathway (erg3,
erg4, erg5, and erg24) were cultivated at 24 °C, shifted to 37 °C for
15 min, and radiolabeled, and Pma1p stability was analyzed by immu-
noprecipitation and quantified using a phosphorimager. B, inhibition of
sterol biosynthesis does not affect the biogenesis of Pma1p. Cells lack-
ing steryl esters (are1 are2, and RSY1825) were cultivated at 24 °C,
treated with terbinafine (30 g/ml) for the time indicated, and shifted to
37 °C for 15 min in the presence of the drug, and the stability of newly
synthesized Pma1p was examined by pulse-chase analysis. C, terbin-
afine efficiently blocks de novo synthesis of ergosterol without affecting
the stability of Pma1p. are1 are2 double mutant cells were incubated
with terbinafine for the time indicated and labeled with [3H]methionine
(10 Ci/ml) for 2 h, and lipids were extracted, saponified, and analyzed
by thin layer chromatography. are1 are2 double mutant cells were
incubated with terbinafine for 4 h, and detergent resistance of newly
synthesized Pma1p was analyzed and quantified as described in Fig.
2B. The data shown in A	C represent one of two independent experi-
ments with essentially the same results. D, subcellular localization of
Pma1p-GFP in sterol mutants. Ergosterol biosynthetic mutants of the
indicated genotype expressing Pma1p-GFP were shifted to 37 °C for 2 h
and analyzed by fluorescence microscopy. are1 are2 double mutant
cells expressing Pma1p-GFP were incubated with terbinafine for the
time indicated and analyzed by fluorescence microscopy. Bar, 5 m.
FIG. 4. ER synthesized ergosterol is not required for Pma1p
biogenesis. hem1 mutant cells (YRS1707) were grown in media con-
taining either ALA, ergosterol, or cholesterol for more than 48 h, and
the stability of newly synthesized Pma1p was examined by pulse-chase
analysis. Quantification of Pma1p levels is shown in the graph. The
data shown represent one of two independent experiments with essen-
tially the same results. The subcellular localization of Pma1p-GFP in
hem1 mutant cells cultivated in the presence of ALA, ergosterol, or
cholesterol was examined by fluorescence microscopy. Bar, 5 m.
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transported to the plasma membrane. These results thus rein-
force the notion that endogenously synthesized ergosterol is
dispensable for Pma1p biogenesis, indicating that sorting of
Pma1p is clearly distinct from the “raft-dependent” sorting of
other polytopic plasma membrane proteins, such as that of the
tryptophan permease (2).
Sphingolipid Head Group Maturation and Hydroxylation
Are Dispensable for Surface Delivery of Pma1p—To further
define the sphingolipid requirement for Pma1p biogenesis, we
examined Pma1p turnover in a large number of mutants that
affect defined steps along the sphingolipid biosynthetic path-
way (for review, see Refs. 15–17). These mutants can be
grouped according to the step at which they affect sphingolipid
synthesis (see Fig. 1). There are mutations that affect long
chain base synthesis (lcb1-100 and tsc3), long chain base
phosphorylation (lcb4 and lcb5), dephosphorylation (lcb3
and ysr3) and degradation (dpl1), hydroxylation of the long
chain base (sur2) or the C26 fatty acid (scs7), ceramide
synthesis (lac1 and lag1) and degradation (ydc1 and
ypc1), degradation of IPC (isc1), head group maturation of
IPC to mannosyl-inositolphosphorylceramide (sur1 and
csg2), and maturation of mannosyl-inositolphosphorylceram-
ide to mannosyl-diinositolphosphorylceramide (ipt1). With
the exception of lcb1-100 and tsc3, none of the tested mutants
displayed an increased turnover of Pma1p (Fig. 5) (data not
shown). Examination of Pma1p-GFP in these mutants revealed
surface staining in all of the mutants, except lcb1-100 and
tsc3, indicating that the newly made Pma1p is not only stable
but also transported to the cell surface (Fig. 5) (data not
shown). These results are consistent with previous observa-
tions that lcb1-100 affects Pma1p turnover (5, 23, 24) and that
defects in mannosyl-inositolphosphorylceramide synthesis do
not affect Pma1p sorting from the late Golgi apparatus (41).
Moreover, they suggest that sphingolipid synthesis up to IPC,
but no specific structural feature on the sphingolipid molecule,
is critically important for Pma1p biogenesis.
Acyl Chain Elongation Is Required for Pma1p Biogenesis—
Next, we tested whether mutations that affect the synthesis of
the ceramide-bound C26 fatty acid interfere with Pma1p bio-
genesis. Mutations in components of the elongase complex re-
sult in lower levels of the mature C26 fatty acid rather than in
a defined shortening of the very long chain fatty acid, as is the
case in elo3 (18, 19, 21, 22). Analysis of Pma1p in these
elongation mutants revealed a temperature-dependent desta-
bilization of Pma1p and vacuolar localization of Pma1p-GFP in
elo2/fen1, acb1, acc1ts, and tsc13ts (18, 19, 21, 22) (Fig. 6).
These results indicate that it is not only the length of the very
long acyl chains but also their levels that are critically impor-
tant for biogenesis of Pma1p. YBR159 encodes a major 3-ke-
toreductase of the fatty acid elongase, but its function is redun-
dant with that of another ketoreductase, Ayr1p (20). Because
very long chain fatty acid synthesis is essential, the redun-
dancy between YBR159 and AYR1 is likely to account for the
viability of a ybr159 mutant and may also explain why this
mutant does not affect turnover of Pma1p. A defect in ELO1,
which is required for elongation of C14 fatty acids to C16/C18
fatty acids (42, 43), also affects Pma1p stability, but degrada-
tion of Pma1p is much slower compared with mutants that
affect elongation to C26. Whether destabilization of Pma1p in
the elo1 mutant is due to possible indirect effects of a lack of
Elo1p on the synthesis of C26 remains to be established. How-
ever, the observation that rapid destabilization and vacuolar
localization of Pma1p is observed only if elongation to C26 but
not to C16/C18 fatty acids is impaired indicates that C26 syn-
thesis has a more specific role in Pma1p biogenesis.
Elongase Mutants Affect Detergent Resistance of Newly Syn-
thesized Pma1p—To determine whether the acyl chain elon-
FIG. 5. Sphingolipid requirement for Pma1p stability. Biogen-
esis of Pma1p was examined in cells with defects at early steps along
the sphingolipid pathway. lcb1-100, sur2, and tsc3mutant cells were
cultivated at 24 °C and shifted to 30 °C or 37 °C for 15 min, and Pma1p
stability was examined by pulse-chase analysis and immunoprecipita-
tion. Levels of Pma1p were quantified using a phosphorimager. The
data shown represent one of two independent experiments with essen-
tially the same results. The subcellular localization of Pma1p-GFP in
lcb1-100, sur2, and tsc3 was examined by fluorescence microscopy.
Arrows indicate localization of Pma1p-GFP in multi-lobed vacuoles.
Bar, 5 m.
FIG. 6. Acyl chain elongation is required for Pma1p stability.
A, biogenesis of Pma1p was examined in mutants that affect acyl chain
elongation. Cells with the indicated genotype were cultivated at 24 °C,
split, and incubated at either 24 °C or 37 °C for 15 min prior to pulse-
labeling and immunoprecipitation. Levels of Pma1p were quantified
using a phosphorimager. The data shown represent one of two inde-
pendent experiments with essentially the same results. B, the subcel-
lular localization of Pma1p-GFP in the elongation mutants was exam-
ined by fluorescence microscopy. Cells of the indicated genotype
expressing Pma1p-GFP were cultivated at 24 °C, split, and incubated at
either 24 °C or 37 °C for 2 h before microscopic examination. Arrows
indicate localization of Pma1p-GFP in vacuoles. Bar, 5 m.
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gase mutants elo2, acb1, acc1ts, and tsc13ts, which condition-
ally destabilize Pma1p, also affect detergent solubility of
Pma1p, the mutants were deleted for PEP4 to prevent degra-
dation of mistargeted Pma1p in the vacuole. Cells were then
pulse-labeled at either 24 °C or 37 °C, and the detergent solu-
bility of newly synthesized Pma1p was examined as described
for Fig. 2B. This analysis revealed that Pma1p rapidly acquired
detergent resistance in the elongase mutants when cells were
pulse-labeled at 24 °C (Fig. 7). At 37 °C, however, the majority
of newly synthesized Pma1p was present in the detergent-
soluble fraction at the 5 min time point, and only a small
increase in the proportion of Pma1p that resisted detergent
extraction was observed over time. These results indicate that
all the elongase mutants that conditionally affect the stability
of newly synthesized Pma1p also affect its detergent resist-
ance. The fact that a mutation in ELO1 did not affect detergent
solubility of Pma1p is consistent with the slow turnover of
Pma1p observed in this mutant.
The Role of Long Chain Base and Ceramide Signaling in
Pma1p Turnover—Elongase mutants have previously been
shown to contain elevated levels of long chain bases and re-
duced levels of ceramide, both of which are potential signaling
molecules (18, 19, 44–46). To test whether destabilization of
Pma1p is due to a defect in lipid signaling rather than an
aberrant membrane structure, we examined Pma1p stability
under conditions in which long chain base or ceramide synthe-
sis was inhibited by genetic and pharmacological means.
Therefore, Pma1p turnover was examined in elo3 mutant
cells treated with myriocin (20 g/ml) to block long chain base
synthesis and in elo3 treated with fumonisin B1 (75 g/ml) to
inhibit ceramide production. Inhibition of long chain base or
ceramide synthesis failed to stabilize Pma1p, indicating that
elevated long chain base or ceramide levels do not account for
the increased turnover of Pma1p (Fig. 8A). To corroborate these
results, a mutant with chronically low levels of ceramide, lcb1-
100, was combined with a mutation in ELO3. In the resulting
lcb1-100 elo3 double mutant, newly synthesized Pma1p was
stable at 24 °C but destabilized at 30 °C and 37 °C, as observed
in an lcb1-100 mutant alone (Fig. 8A). Thus, no synthetic
alleviation or enhancement of the phenotype of either single
mutant was observed in the double mutant. These results are
in agreement with the proposal that the conditional turnover of
Pma1p in elongase mutant cells is not due to a defect in long
chain base or ceramide signaling but may be due to reduced
levels and/or the aberrant structure of ceramides made in these
cells.
Increased levels of long chain base induce the degradation of
cell surface permeases (44, 47, 48). Exogenously added long
chain base (10 M), however, did not induce increased turnover
of newly synthesized Pma1p in wild-type cells at either 24 °C or
37 °C. Similarly, exogenously added long chain base failed to
rescue the increased turnover of Pma1p in elo3 mutant cells
and did not substitute for heat treatment (37 °C), which is
known to increase long chain base levels (49, 50) (Fig. 8B).
These results thus suggest that the increased turnover of newly
synthesized Pma1p in the elongase mutant is distinct from the
long chain base-induced degradation of cell surface permeases
and that mistargeting of Pma1p is not due to a long chain base-
or ceramide-mediated signaling event.
DISCUSSION
In this study, we have characterized the lipid requirements
for surface delivery and stabilization of a newly synthesized
integral plasma membrane protein, Pma1p. The results of our
analyses indicate that synthesis of sphingolipids up to IPC and
acyl chain elongation are critically important for Pma1p bio-
genesis. A block in ergosterol synthesis or defects along the
ergosterol biosynthetic pathway that result in the formation of
aberrant sterols, on the other hand, do not affect Pma1p bio-
genesis or its association with detergent-resistant membranes.
Even the complete substitution of endogenously synthesized
ergosterol by exogenously supplied cholesterol did not affect
Pma1p biogenesis. These results thus indicate that sterols are
less important for surface transport of Pma1p. Remarkably,
various defects in nonessential pathways of phospholipid syn-
thesis as imposed by mutations in CHO1 (required for the
synthesis of phosphatidylserine), in both PEM1 and PEM2
(required for the methylation of phosphatidylethanolamine to
phosphatidylcholine) or in PSD1 and PSD2 (required for the
decarboxylation of phosphatidylserine to phosphatidylethanol-
FIG. 7. Elongase mutants affect detergent extractability of
newly synthesized Pma1p. Cells of the indicated genotype were
pulse-labeled at either 24 °C or after a pre-shift to 37 °C for 15 min.
Samples were removed at the indicated time points after chase addition
and split into a total fraction (T) and a second fraction that was ex-
tracted with 1% Triton X-100 for 30 min on ice. The detergent fraction
was centrifuged at 100,000  g for 1 h to yield a detergent-resistant
pellet (P) and a detergent-soluble fraction (S). Pma1p was immunopre-
cipitated and analyzed by gel electrophoresis. Quantification of Pma1p
levels in the detergent-resistant pellet as a function of temperature and
time is shown in the graphs. The data shown represent one of two
independent experiments with essentially the same results.
FIG. 8. Long chain base signaling does not account for Pma1p
turnover in elo3. A, a block in long chain base or ceramide synthesis
fails to stabilize Pma1p in the elongase mutant. elo3mutant cells were
cultivated at 24 °C, pre-incubated with either myriocin (20 g/ml) or
fumonisin B1 (75 g/ml) for 15 min, and then shifted to 37 °C for 15
min. lcb1-100 elo3 double mutant cells (YRS1986) were cultivated at
24 °C, split, and incubated at 24 °C, 30 °C, or 37 °C for 15 min. Cells
were labeled, and Pma1p turnover was examined by immunoprecipita-
tion. B, long chain base (PHS, phytosphingosine) addition does not
stabilize Pma1p in elo3. Wild-type and elo3 mutant cells were culti-
vated at 24 °C, incubated with phytosphingosine (10 M) for 2 h, and
either left at 24 °C or shifted to 37 °C for 15 min prior to labeling and
immunoprecipitation of Pma1p. The data shown represent one of two
independent experiments with essentially the same results.
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amine) did not destabilize Pma1p.2 The sphingolipid require-
ment for Pma1p biogenesis thus appears to be rather specific
and cannot be explained by a more general defect in membrane
structure.
The examination of the sphingolipid requirement for Pma1p
biogenesis using drugs that block essential steps or mutations
in nonessential or redundant steps along the sphingolipid bio-
synthetic pathway revealed some of the characteristics of this
lipid requirement.
(i) Inhibition of the synthesis of either long chain base, cer-
amide, or IPC results in conditional turnover of Pma1p, sug-
gesting that flux through the pathway up to IPC is required for
proper biogenesis of Pma1p. A block in long chain base, ceram-
ide, and IPC biosynthesis, on the other hand, may induce
Pma1p turnover indirectly, for example, through accumulation
of the respective biosynthetic precursors, long chain base, cer-
amide, or the free very long chain fatty acids. Such indirect
effects have been suggested to account for the lethality of a
defect in IPC synthesis, which becomes dispensable under con-
ditions in which ceramide does not accumulate to toxic levels
(10).
(ii) The observation that mutations that block sphingolipid
hydroxylation or head group maturation do not affect Pma1p
biogenesis indicates that the potential of these lipid modifica-
tions to engage in hydrogen bonds is not critical for Pma1p
stability (51).
(iii) All mutations that affect fatty acid elongation and the
synthesis of the ceramide-bound C26 fatty acid conditionally
destabilize newly synthesized Pma1p. Defects in acyl chain
elongation may affect sphingolipid metabolism in at least three
ways. First, elongase mutants have reduced levels of ceramide,
most likely because the mature C26 fatty acid is the preferred
substrate for the ceramide synthase (44, 52). Second, a reduced
efficacy of the ceramide synthase results in the accumulation of
long chain base (18). Third, the ceramide synthesized in elon-
gase mutants has a shorter acyl chain (19, 26). Any one or all of
these factors could account for the increased turnover of newly
synthesized Pma1p. Evidence indicates that accumulation of
long chain base does not account for the increased turnover of
Pma1p. For example, myriocin, by itself, induces Pma1p turn-
over in wild-type cells but fails to rescue Pma1p when applied
to elo3 mutant cells. Correspondingly, an lcb1-100 elo3 dou-
ble mutant still exhibits aberrant Pma1p turnover, and no
synergistic effect of the two mutations on the stability of
Pma1p at either 24 °C or 30 °C is observed. In addition, exog-
enously added long chain base does not induce Pma1p turnover
in either wild-type or elo3 mutant cells. These observations
thus indicate that ceramide levels and/or their substitution
with very long acyl chains is critically important for routing
Pma1p to the cell surface.
Mistargeting of Pma1p is strictly temperature-dependent.
Both protein folding/assembly and membrane structures are
known to be particularly thermo-sensitive. Attempts to stabi-
lize Pma1p by the use of small molecular chaperons were not
successful, suggesting that aberrant protein folding may not be
affected in the lipid mutant. Oligomerization of Pma1p in the
ER is not critical for stability because even monomeric Pma1p
is delivered to the cell surface (23). A possible additive effect of
the elongation defect and the temperature treatment on mem-
brane structure, however, is supported by the fact that mistar-
geting of Pma1p correlates with failure of the protein to acquire
detergent solubility. Mistargeting of Pma1p may thus be due to
an aberrant membrane environment. Such an aberrant mem-
brane domain per se may be sufficient for redirection to the
vacuole. Alternatively, the aberrant membrane environment
may affect the way in which the Pma1p complex is embedded in
the membrane, possibly resulting in the exposure of residues
that are normally covered by the membrane. Such residues
may then be recognized by certain quality control checkpoints,
which are known to recognize membrane proteins with hydro-
philic residues within their transmembrane domains (53).
The precise route that the newly synthesized Pma1p follows
upon mistargeting to the vacuole in the elongase mutants has
not yet been defined. We have previously observed that Pma1p
can be stabilized in an elo3 mutant by inhibiting endocytosis
from the plasma membrane (26), indicating that the protein
reaches the cell surface at least transiently. Mistargeting of
wild-type Pma1p in the elongase mutants, however, shares
many of the characteristics observed for a temperature-sensi-
tive mutant allele of Pma1p, Pma1-7p. Pma1-7p conditionally
looses association with detergent-resistant membranes and is
mistargeted to the vacuole under non-permissive conditions
(24). In the case of Pma1-7p, vacuolar mistargeting occurs
before fusion of Golgi-derived vesicles with the plasma mem-
brane because a late-acting block in secretion, such as that
imposed by a mutation in SEC6 (24), fails to stabilize the
mutant protein. Sorting of Pma1-7p is regulated by a Golgi-
based ubiquitin-dependent quality control system because
mistargeting requires an ubiquitin ligase complex containing
Rsp5p, Bul1p, and Bul2p (54). Whether the same ubiquitin
ligase affects mistargeting of Pam1p in the elongase mutants
remains to be established.
Genetic studies provide evidence that Pma1p can reach the
cell surface by multiple pathways and from within the endoso-
mal system (55, 56). It is thus conceivable that elongase mu-
tants affect sorting of Pma1p not from the Golgi, but from a
subsequent endosomal compartment. Future studies will now
be required to identify the compartment in which mis-sorting of
Pma1p is sphingolipid-dependent.
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